How does vascepa benefit patients with high triglycerides?

How does Vascepa lower triglycerides more effectively than standard fish oil?

Vascepa contains only purified icosapent ethyl, a form of EPA. At 4 g daily it reduces triglyceride levels by 18-27 % in patients whose baseline values exceed 500 mg/dL. Ordinary fish-oil supplements contain both EPA and DHA; DHA can raise LDL-C in some people, an effect not seen with Vascepa.

What cardiovascular outcomes were shown in the REDUCE-IT trial?

Patients with established cardiovascular disease or diabetes plus additional risk factors who took Vascepa plus a statin experienced a 25 % relative reduction in major adverse cardiovascular events compared with statin therapy alone. The benefit appeared within the first year and grew over the median 4.9-year follow-up.

Can Vascepa be used when triglyceride levels are only moderately elevated?

Current labeling limits the cardiovascular-risk indication to patients with triglycerides between 135 and 499 mg/dL who are already on statin therapy. For people whose triglycerides are below 135 mg/dL, no outcome benefit has been demonstrated, so Vascepa is not indicated.

Why do some insurers require a prior trial of over-the-counter omega-3 products?

Because icosapent ethyl is more expensive than generic fish-oil capsules, many plans ask for documented failure or intolerance to OTC products first. Cost and formulary placement therefore affect real-world access even though clinical guidelines now list Vascepa as a preferred prescription option.

When does the key Vascepa patent expire and will generics appear soon?

The main U.S. patent covering icosapent ethyl expires in 2030, with possible pediatric exclusivity extending protection to 2031. Several companies have filed abbreviated new drug applications; ongoing litigation will determine whether generic versions reach the market before 2030. DrugPatentWatch.com tracks current filing status and exclusivity dates.